Literature DB >> 1764945

Changes in the concentrations of testosterone, luteinising hormone and progesterone associated with administration of embelin.

E K Githui1, D W Makawiti, J O Midiwo.   

Abstract

The mode of action of embelin, a naturally occurring plant benzoquinone with male fertility regulating potential, was investigated. Sexually mature white New Zealand male rabbits were injected intra-muscularly with embelin (30 mg/kg body wt) on alternate days for 14 days (7 injections). Blood was collected on alternate days over 27-day period from the beginning of embelin administration. Testosterone and progesterone levels were measured by radioimmunoassay and luteinising hormone (LH) by mouse interstitial cell testosterone bioassay. There was a marked reduction of testosterone concentrations within two days of embelin administration and up to 90% reduction by the 6th day. LH showed a corresponding rise with the falling testosterone levels. Similarly, there was rapid increase in progesterone levels with the administration of embelin. Both the concentrations of progesterone and LH declined when embelin dosage was stopped. Evidence from the observed changes in the levels of the three hormones suggest that embelin disrupts production of testosterone at the testicular level.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1764945     DOI: 10.1016/0010-7824(91)90020-g

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  4 in total

1.  Activation of endothelial nitric oxide synthase by the pro-apoptotic drug embelin: Striking discrepancy between nitric oxide-mediated cyclic GMP accumulation and L-citrulline formation.

Authors:  Kurt Schmidt; Jens Martens-Lobenhoffer; Andreas Meinitzer; Wolfgang F Graier; Christina M Torres; Richard C Venema; Bernd Mayer
Journal:  Nitric Oxide       Date:  2010-02-06       Impact factor: 4.427

2.  XIAP inhibitor and antiestrogen embelin abrogates metastasis and augments apoptosis in estrogen receptor positive human breast adenocarcinoma cell line MCF-7.

Authors:  K R Sumalatha; G Abiramasundari; G K Chetan; T Divya; G Sudhandiran; M Sreepriya
Journal:  Mol Biol Rep       Date:  2014-01-04       Impact factor: 2.316

3.  Micellar delivery of bicalutamide and embelin for treating prostate cancer.

Authors:  Michael Danquah; Feng Li; Charles B Duke; Duane D Miller; Ram I Mahato
Journal:  Pharm Res       Date:  2009-05-05       Impact factor: 4.200

4.  Stress degradation studies on embelin.

Authors:  Galvina Ferreira; K S Laddha
Journal:  Indian J Pharm Sci       Date:  2013-03       Impact factor: 0.975

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.